Characterization and Phase 1 Trial of a B Cell Activating Anti-CD73 Antibody for the Immunotherapy of COVID-19

Stephen B. Willingham, Gerard Criner, Craig Hill, Shenshen Hu, Jenny A. Rudnick, Barbara Daine-Matsuoka, Jessica Hsieh, Haider Mashhedi, Andrew N. Hotson, Joshua Brody, Thomas Marron, Emily Piccione, Joseph J. Buggy, Suresh Mahabhashyam, William B. Jones, Mehrdad Mobasher, Richard A. Miller
doi: https://doi.org/10.1101/2020.09.10.20191486

Data Availability

Further information and requests for resources and/or reagents should be directed to Dr. Stephen Willingham (swillingham{at}corvuspharma.com).

Back to top
Posted September 15, 2020.
Download PDF

Supplementary Material

Data/Code
Email
Characterization and Phase 1 Trial of a B Cell Activating Anti-CD73 Antibody for the Immunotherapy of COVID-19
Stephen B. Willingham, Gerard Criner, Craig Hill, Shenshen Hu, Jenny A. Rudnick, Barbara Daine-Matsuoka, Jessica Hsieh, Haider Mashhedi, Andrew N. Hotson, Joshua Brody, Thomas Marron, Emily Piccione, Joseph J. Buggy, Suresh Mahabhashyam, William B. Jones, Mehrdad Mobasher, Richard A. Miller
medRxiv 2020.09.10.20191486; doi: https://doi.org/10.1101/2020.09.10.20191486
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area